PASADENA: A Study to Evaluate Intravenous RO7046015 (PRX002) in Participants with Early Parkinson's Diseas (H-41067)
This is a research study of a drug called RO7043015. RO7046015 is being developed for the possible treatment of Parkinson's disease.
RO7046015 is a type of medication called a "monoclonal antibody." Antibodies are proteins produced by your body as a part of the immune response. Monoclonal antibodies are antibodies which have been engineered to recognize and bind to a specific type of protein. RO7046015 binds to a protein called alpha synuclein, which is found in the human brain. In person with PD, alpha synuclein clumps to form insoluble plaques in certain areas of the brain and other tissues which damages nerve cells and is associated with symptoms of the disease. RO7046015 may bind to and clear these pathological forms of alpha synuclein and block the spread to healthy neurons, potentially slowing the course of Parkinson's disease.